Accelerating drug discovery and development
Accelerating drug discovery and development

Biomarkers  |  Biosimilars

slide-2
slide-2

Licensing Opportunities

  • Panel of diabetic kidney disease biomarkers validated at high stringency with an antibody platform

Biomarkers

Diagnostics / Prognostics

  • Proven Mass Spectrometry Platforms
  • Discovery for Diabetes, Alzheimer’s, Cancer Markers
  • Cross-Validation with Antibody Platforms
  • Access to Highly Curated Clinical Samples

Therapeutics

Drug Discovery

  • Accelerated High Throughput Drug Discovery System
  • Native Venom Derived Platform  
  • Antimicrobial / Analgesic Molecules
  • Green Tech Applications

Accredited Laboratory

ISO 17025 quality

Proteomics International has world leading laboratory accreditation to International Standard ISO / IEC 17025:2005 for provision of proteomics services

  • April 15th 2014

    Proteomics International biomarker study moves closer to a CDx test … Continue reading

    February 28th 2014

    Proteomics International Signs Agreement with inVentiv Health Clinical Partnership offers … Continue reading

    November 5th 2013

    Driving drug and diagnostic development in renal biomarkers - FierceBiotech’s … Continue reading